Mylan to invest $1 Billion in India on capex in 6 years

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

America’s AI Action Plan Boosts Pharmaceutical Innovation

Accelerating Pharmaceutical and Biopharmaceutical Innovation through America’s AI Action...

Trump To Roll-Out 340B Drugs Discount Program in 2026

The Trump administration is going to pilot a voluntary...

60-Day Window by Trump for Firms to Lower Their Drug Prices

President Donald Trump of the USA has sent letters...

Canada-UK Partnership Integrates Bioreactor Technologies

In a recent move, an international initiative is going...

World Pharma Today / News / India – Mylan, a global generic and specialty Pharmaceuticals Company registered in the Netherlands has confirmed that in the coming 5-6 years it will invest one billion USD on Capex in India. The move comes considering India’s position in the World Pharma supply chain. As per Mylan’s Global President and Executive Director, Rajeev Malik, the company has been investing close to USD 400-500 million on Capex annually and half of it happens to be in India. In the last seven years, the company has already invested one billion dollars in the country to upkeep as well as expand its activities. The company has a robust network in India and wishes to keep the investment going.

Mylan currently has 21 centers in the country with around 15000 employees. It is well to be noted that out of 44 plants across the world, 21 are located in India. This goes on to show how much big a market India is for them. They are currently doing around 1000 crores a year. Rajeev Malik is of an opinion that the Government needs to incentivize R & D activities that are undertaken by the Pharma companies majorly on drug development. China is currently focusing a lot on this and competing with large US and European corporations. This is where the top management at Mylan feels that India should catch up. Because once the R & D gets incentivized, infrastructure gets created which in turn puts fewer burdens on companies.

Latest stories

Related stories

America’s AI Action Plan Boosts Pharmaceutical Innovation

Accelerating Pharmaceutical and Biopharmaceutical Innovation through America’s AI Action...

Trump To Roll-Out 340B Drugs Discount Program in 2026

The Trump administration is going to pilot a voluntary...

60-Day Window by Trump for Firms to Lower Their Drug Prices

President Donald Trump of the USA has sent letters...

Canada-UK Partnership Integrates Bioreactor Technologies

In a recent move, an international initiative is going...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back